Skip to main content
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 147.00
Day High 149.46
Open:147.52
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Health Canada Approves New Indication for STELARA®* (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
- CNW Group - Mon Jan 27, 6:31AM CST
CNW Group - CMTX
Mon Jan 27, 6:31AM CST
In the Phase 3 pivotal trial, nearly 44 per cent of patients receiving STELARA(®) subcutaneous (SC) injections every 8 weeks were in clinical remission at one year
Global Stroke Treatment Market Report 2019-2027 Featuring Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Roche, Johnson & Johnson Services, Sanofi, Amgen, Biogen, and AstraZeneca
- PR Newswire - Fri Jan 24, 3:45PM CST
PR Newswire - CMTX
Fri Jan 24, 3:45PM CST
The "Stroke Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.
The European Commission Approves Expanded Use of Janssen's STELARA(R) (ustekinumab) for the Treatment of Paediatric Patients With Moderate to Severe Plaque Psoriasis
- BusinessWire - Thu Jan 23, 3:00AM CST
BusinessWire - CMTX
Thu Jan 23, 3:00AM CST
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has approved the expanded use of STELARA(R) (ustekinumab) for the treatment of paediatric patients (ages 6-11) with moderate to severe plaque psoriasis. Ustekinumab was previously approved for use in adolescent and adult patients with plaque psoriasis, aged 12 years and older, and is now the first available biologic treatment in this patient population to selectively address the IL'23/IL'12 pathway, an important therapeutic target for the condition.(1)
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 141.38 +5.21% increase
on 01/07/20
Period Open:145.75
Price movement based on the high, low and last over the given period.
150.17 -0.95% decrease
on 01/21/20
+3.00 (+2.06%) increase
since 12/27/19
3-Month 128.51 +15.75% increase
on 10/28/19
Period Open:128.35
Price movement based on the high, low and last over the given period.
150.17 -0.95% decrease
on 01/21/20
+20.40 (+15.89%) increase
since 10/25/19
52-Week 126.10 +17.96% increase
on 10/24/19
Period Open:128.23
Price movement based on the high, low and last over the given period.
150.17 -0.95% decrease
on 01/21/20
+20.52 (+16.00%) increase
since 01/25/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies